If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Issue of Equity

21 Jul 2006 07:00

ReGen Therapeutics PLC21 July 2006 ReGen Therapeutics Plc places 111,000,000 of shares ReGen Therapeutics Plc ("ReGen" or the "Company") announces that it has todayplaced through its brokers J M Finn & Co with new and existing shareholders111,000,000 new ordinary shares at 1p per share to raise Β£1,110,000, beforeexpenses ("Placing") Application will be made for these 111,000,000 new ordinary shares to beadmitted to the AIM Market of the London Stock Exchange Plc and dealings areexpected to commence at 8am on 27th July 2006. Executive Chairman Percy Lomax commented, "This money will be used for thecommercialisation of Colostrinin(TM)as per the recently announced deal withMetagenics Inc. and carry out further work on the development of its constituentpeptides as potential pharmaceuticals as well as providing additional resourcesfor the development of new formulations of zolpidem for the rehabilitation ofpeople with brain injury. This has received considerable positive publicity inthe national press and a documentary film is currently being discussed with anumber of producers. Depending upon the actual timing of anticipated revenuesfrom the commercialisation of ColostrininTM, the achievement of developmentmilestones and whether other commercial opportunities present themselves, it maybe necessary to raise additional amounts of capital in the future." All new ordinary shares will rank pari passu with the existing ordinary shares of 0.1p each in the Company. Two Non-Executive Directors are subscribing for new ordinary shares in theplacing: Mr Peter Garrod is subscribing for 2,500,000 new ordinary shares makinghis total holding 66,250,000 representing 9.54% of the enlarged share capital.Mr Keith Corbin is subscribing for 1,000,000 new ordinary shares making histotal holding 1,105,000 representing 0.16% of the enlarged share capital. For further information, please contact: Andrew MarshallGreycoat CommunicationsTel. 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Mar 202112:30 pmRNSAccustem Update
30th Mar 20217:00 amRNSP2 Study in Moderate to Severe Covid-19 Patients
29th Mar 20211:02 pmRNSUpdated: Gabriele Cerrone, Bloomberg Interview
29th Mar 20217:00 amRNSChairman of Tiziana to give interview on Bloomberg
26th Feb 20217:00 amRNSTiziana Interview to Air on Bloomberg TV
16th Feb 20212:37 pmRNSTiziana at BIO CEO & Investor Digital Conference
5th Feb 20217:10 amRNSDirector/PDMR Shareholding
5th Feb 20217:00 amRNSAPPOINTMENT OF DIRECTOR
3rd Feb 20217:00 amRNSCEO exclusive interview to discuss COVID-19 Trial
2nd Feb 20214:41 pmRNSSecond Price Monitoring Extn
2nd Feb 20214:36 pmRNSPrice Monitoring Extension
2nd Feb 20219:05 amRNSSecond Price Monitoring Extn
2nd Feb 20219:00 amRNSPrice Monitoring Extension
2nd Feb 20217:00 amRNSPositive Data: Nasal Administration of Foralumab
27th Jan 20217:00 amRNSTiziana files F-3 Statement with U.S. SEC
26th Jan 20217:00 amRNSUpdated corporate presentation
20th Jan 202111:04 amRNSB. Riley Virtual Oncology Investor Conference
20th Jan 20217:00 amRNSAIM Delisting and Admission to the Main Market
13th Jan 20217:00 amRNSAppointment of Chief Medical Officer
11th Jan 20214:46 pmRNSTiziana at J.P. Morgan Healthcare Conference 2021
11th Jan 20212:48 pmRNSTiziana to Present at Biotech Showcase Digital
4th Jan 20219:05 amRNSSecond Price Monitoring Extn
4th Jan 20219:00 amRNSPrice Monitoring Extension
4th Jan 20217:00 amRNSCompletion of Foralumab Clinical Trial in Brazil
18th Dec 202011:13 amRNSPublication of Prospectus
17th Dec 20203:00 pmRNSNotification of Admission to the Main Market
10th Dec 20207:00 amRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTiziana Life Sciences to Host Investor Update Call
18th Nov 20202:00 pmRNSDirector/PDMR Shareholding
11th Nov 20207:00 amRNSPhase 1b/2 Clinical Trial - Crohn's Disease
9th Nov 20202:05 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
2nd Nov 20209:05 amRNSSecond Price Monitoring Extn
2nd Nov 20209:00 amRNSPrice Monitoring Extension
2nd Nov 20207:00 amRNSInitiation of Clinical Trial for COVID-19 Patients
29th Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
29th Oct 20207:00 amRNSDemerger Update and Timetable Confirmation
28th Oct 20207:00 amRNSIssue of Equity on Exercise of Warrants
27th Oct 20204:00 pmRNSDemerger of StemPrintER
26th Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
22nd Oct 20204:36 pmRNSIssue of Equity on Exercise of Warrants
21st Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
20th Oct 20207:00 amRNSIssue of Equity on Exercise of Warrants
2nd Oct 202012:00 pmRNSResult of GM
30th Sep 20207:00 amRNSHalf-year Report
25th Sep 20204:40 pmRNSSecond Price Monitoring Extn
25th Sep 20204:35 pmRNSPrice Monitoring Extension
25th Sep 20207:00 amRNSInterview - Bloomberg International
21st Sep 20202:11 pmRNSPublication of Research Note
21st Sep 20207:00 amRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.